Marina Biotech Inc., of Bothell, Wash., said preclinical data showed a miRNA mimetic formulated using its liposomal-based delivery technology, SMARTICLES, demonstrated inhibition of tumor growth in an orthotopic liver tumor, as indicated by a decrease in systemic liver tumor biomarker alpha-feto protein and a decrease in tumor weight of more than 80 percent.